A boceprevir failure in a patient infected with HCV genotype 1g: Importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy

Abstract

A patient classified as HCV-1a-positive by both LiPA Siemens 2.0 and Abbott RealTime HCV Genotype II was instead found to be infected with HCV-1g, as determined by phylogenetic analysis of NS3 sequences. HCV-1g NS3 sequences available to date naturally harbour the resistance substitution T54S, plus P131S and L135F changes, located in the highly conserved NS3 positions within the boceprevir-binding site, as determined by structural modelling. HCV-1g NS3 sequences show some similarities to HCV-4 and arepoorly responsive to interferon/ribavirin and to boceprevir/telaprevir; this patient was also a nullresponder to boceprevir treatment. Baseline genotypic resistance testing may provide crucialinformation for the management of first-generation protease-inhibitorbased regimens, including both HCV genotype/subtype and natural resistance. © 2013 International Medical Press.